HCPCS Level II code J1071 identifies a 1 mg injection of testosterone cypionate, an androgen replacement therapy commonly used in male hypogonadism and certain gender-affirming care. As a drug-specific HCPCS Level II code, J1071 is used on medical claims to report administered units of this injectable medication and matters for billing, coverage determinations, and drug utilization monitoring across payers nationally. Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for testosterone cypionate injections, common sites of service where administration occurs, and the billing implications of using an HCPCS Level II drug code. The publication outlines typical coverage considerations, payer variation in drug benefit management, and common billing challenges such as unit reporting and site-specific payment policies. It also summarizes available benchmarks and notable policy updates that affect injectable testosterone products at a national level. This resource is intended for billing professionals, clinicians who order or administer injectable therapies, and policy analysts seeking a practical reference on use and reporting of HCPCS Level II code J1071.